Answers are grounded in this paper and cite their sources.
Spatial Rho-family signaling at adhesive interfaces determines how cells generate traction, remodel adhesions, change shape and migrate. DLC1 (deleted in liver cancer 1; STARD12) is a major regulator of this system and a chromosome 8p tumor suppressor first identified in hepatocellular carcinoma (HCC). Its effects cannot be inferred from expression alone: catalytic competence, subcellular localization, scaffold engagement and regulatory state determine how DLC1 constrains Rho-family signaling. Here, we first define the spatial and dynamic logic of Rho signaling, then organize DLC1 biology by family context, domain architecture, localization and regulation. We synthesize evidence connecting DLC1 impairment to RhoA/ROCK/MLC2 signaling, actomyosin contractility, focal-adhesion and junctional remodeling, invasion and mechanotransduction. HCC is treated as the primary disease anchor, while pan-cancer, fibroblast and endothelial findings are separated according to their model-specific evidence. YAP/TAZ-associated signaling, functional-state biomarkers, hepatocyte ploidy and therapeutic resistance are discussed as context-dependent or testable hypotheses where direct evidence remains limited.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: